These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 23372058)

  • 1. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
    Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
    J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.
    Castagna A; Spagnuolo V; Galli L; Vinci C; Nozza S; Carini E; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Lazzarin A;
    AIDS; 2014 Sep; 28(15):2269-79. PubMed ID: 25058680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
    Di Giambenedetto S; Fabbiani M; Quiros Roldan E; Latini A; D'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Di Pietro M; Mondi A; Ciccarelli N; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;
    J Antimicrob Chemother; 2017 Apr; 72(4):1163-1171. PubMed ID: 28093483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
    Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
    Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression.
    Hung TC; Chen GJ; Cheng SH; Chen JH; Wei JL; Cheng CY; Hung CC
    J Microbiol Immunol Infect; 2019 Dec; 52(6):865-871. PubMed ID: 31422059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
    Lombardi F; Belmonti S; Quiros-Roldan E; Latini A; Castagna A; D'Ettorre G; Gagliardini R; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S;
    J Antimicrob Chemother; 2017 Jul; 72(7):2055-2059. PubMed ID: 28333353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
    Fabbiani M; Gagliardini R; Ciccarelli N; Quiros Roldan E; Latini A; d'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Del Pin B; Lombardi F; D'Avino A; Focà E; Colafigli M; Cauda R; Di Giambenedetto S; De Luca A;
    J Antimicrob Chemother; 2018 Jul; 73(7):1955-1964. PubMed ID: 29668978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
    Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
    J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
    Haas DW; Zala C; Schrader S; Piliero P; Jaeger H; Nunes D; Thiry A; Schnittman S; Sension M;
    AIDS; 2003 Jun; 17(9):1339-49. PubMed ID: 12799555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.
    Bonora S; Calcagno A; Vigano O; Bigliano P; Marinaro L; Colella E; Orofino G; Trentini L; Tettoni MC; D'Avolio A; Mercadante S; Galli M; Di Perri G; Rusconi S
    Curr HIV Res; 2014; 12(5):339-46. PubMed ID: 25106410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.